These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 20478589)

  • 1. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
    Klotz LH
    Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.
    Loblaw A; Zhang L; Lam A; Nam R; Mamedov A; Vesprini D; Klotz L
    J Urol; 2010 Nov; 184(5):1942-6. PubMed ID: 20846681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
    Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
    J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
    Klotz L; Zhang L; Lam A; Nam R; Mamedov A; Loblaw A
    J Clin Oncol; 2010 Jan; 28(1):126-31. PubMed ID: 19917860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling prostate specific antigen kinetics in patients on active surveillance.
    Zhang L; Loblaw A; Klotz L
    J Urol; 2006 Oct; 176(4 Pt 1):1392-7; discussion 1397-8. PubMed ID: 16952640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
    Tollefson MK; Blute ML; Rangel LJ; Karnes RJ; Frank I
    J Urol; 2010 Sep; 184(3):925-9. PubMed ID: 20643452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
    Klotz L
    Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance.
    Al Otaibi M; Ross P; Fahmy N; Jeyaganth S; Trottier H; Sircar K; Bégin LR; Souhami L; Kassouf W; Aprikian A; Tanguay S
    Cancer; 2008 Jul; 113(2):286-92. PubMed ID: 18484590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH; Nam RK
    Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.